Tag: Parkinson's disease

Olatec Therapeutics set to launch dapansutrile Phase 2 trial in Parkinson’s disease

businessnewstoday- February 20, 2024

Olatec Therapeutics, Inc. (Olatec), a leader in the field of selective NLRP3 inhibitors, has embarked on a  journey to tackle Parkinson's disease, a neurodegenerative disorder ... Read More

Inhibikase Therapeutics advances Parkinson’s disease treatment with risvodetinib clinical trials

businessnewstoday- January 29, 2024

Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company, has announced the publication of its Phase 1 clinical studies for risvodetinib (risvo), a potential disease-modifying ... Read More

Zydus Lifesciences to launch Phase 2 Parkinson’s disease trial of ZYIL1

businessnewstoday- December 17, 2023

Zydus Lifesciences Limited, a globally recognized pharmaceutical company, has recently obtained the USFDA's approval to commence Phase II clinical study of its NLRP3 inhibitor, ZYIL1, ... Read More

AbbVie to acquire Cerevel Therapeutics for $8.7bn to expand neuroscience research

businessnewstoday- December 7, 2023

AbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) have announced a definitive agreement in which AbbVie will acquire Cerevel Therapeutics. The transaction, valued at ... Read More

SPARC achieves enrollment goal in PROSEEK Phase 2 Parkinson’s trial

businessnewstoday- October 30, 2023

Sun Pharma Advanced Research Company Ltd. (SPARC) has announced the successful completion of patient enrollment for the PROSEEK study, a significant global Phase 2 clinical ... Read More

ABL Bio, Sanofi sign $1bn deal for Parkinson’s candidate ABL301

pallavi123- January 14, 2022

ABL Bio has bagged a global collaboration and licensing deal worth up to $1.06 billion with Sanofi to develop and commercialize its drug candidate ABL301 ... Read More

Lilly wraps up acquisition of gene therapy company Prevail Therapeutics

pharmanewsdaily- January 23, 2021

Eli Lilly and Company (Lilly) has completed its previously announced deal worth up to $1.04 billion of US gene therapy company Prevail Therapeutics. The US ... Read More

Lilly to acquire US gene therapy company Prevail Therapeutics in $1bn deal

pharmanewsdaily- December 16, 2020

Eli Lilly and Company (Lilly) has signed a deal worth up to $1.04 billion to acquire Prevail Therapeutics, a US gene therapy company engaged in ... Read More

Cerevel launches phase 3 Parkinson’s disease clinical trials for tavapadon

pharmanewsdaily- January 15, 2020

Parkinson’s disease clinical trials : Cerevel Therapeutics, a US biopharma company, has initiated a phase 3 clinical trial program for evaluating tavapadon in Parkinson’s disease ... Read More

resTORbio to stop RTB101 development for symptomatic respiratory illness

pharmanewsdaily- November 18, 2019

resTORbio has discontinued the development of RTB101, a TORC1 inhibitor, for the prevention of clinically symptomatic respiratory illness (CSRI) after the drug failed to meet ... Read More